Last updated: 07/17/2024 17:16:27
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Completed
Completed
Trial overview
Official title: Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Trial description: This study will evaluate the efficacy and safety of two concentrations (0.5 percent [%] and 1%) and two application frequencies (once a day and twice a day) of GSK2894512 cream for the topical treatment in adolescent and adult subjects with atopic dermatitis. Results from this study will be considered when selecting the most appropriate concentration of GSK2894512 cream and application frequency in future clinical studies. This is a multicenter (United States, Canada, and Japan), randomized, double-blind (sponsor-unblind), vehicle-controlled, 6-arm, parallel-group, dose-finding study in adolescent and adult subjects with atopic dermatitis. Two concentrations of GSK2894512 cream (0.5% and 1%) and a vehicle control cream will be equally randomized and evaluated following application to all atopic dermatitis lesions (except on the scalp) once daily (evening) or twice daily (morning and evening) for 12 weeks. This study will consist of 3 periods: up to 4 weeks screening, 12 weeks double-blind treatment, and 4 weeks post-treatment follow-up. The total duration of subject participation will be approximately 16 to 20 weeks. Approximately 270 adolescent and adult males and females subjects with atopic dermatitis will be screened in order to have at least 228 randomized subjects (38 subjects for each of the 6 treatment groups) and approximately 204 evaluable subjects overall. Approximately 30 subjects will be randomized in Japan to achieve at least 24 evaluable Japanese subjects.
Primary purpose:
Treatment
Trial design:
Parallel Assignment
Masking:
Double (Participant, Investigator)
Allocation:
Randomized
Primary outcomes:
Percentage of participants who have an Investigator Global Assessment (IGA) score of clear or almost clear (0 or 1) at Week 12 and a minimum 2 grade improvement in IGA score from Baseline to Week 12 for Intent to treat (ITT) Population
Timeframe: Baseline and up to Week 12
Secondary outcomes:
Mean change from Baseline in weekly average of daily itch/pruritus (numeric rating scale [NRS]) score
Timeframe: Baseline and up to Week 12
Mean percent change from Baseline in weekly average of daily itch/pruritus NRS score
Timeframe: Baseline and up to Week 12
Percentage of participants who achieve a minimum 3- point improvement in itch/pruritus (NRS) from Baseline to each study visit
Timeframe: Week 1, 2, 4, 8, 12, 14, 16, early withdrawal (EW) (up to Week 16)
Mean change from Baseline in eczema area and Severity Index (EASI) score
Timeframe: Week 1, 2, 4, 8, 12, 14, 16, EW (up to Week 16)
Mean percent change from Baseline in EASI score
Timeframe: Weeks 1, 2, 4, 8, 12, 14, 16, EW (up to Week 16)
Percentage of participants with a minimum 2-grade improvement in IGA score from Baseline to each visit
Timeframe: Weeks 1, 2, 4, 8, 12, 14, 16, EW (up to Week 16)
Percentage of participants with an IGA score of 0 or 1 at each visit
Timeframe: Weeks 1, 2, 4, 8, 12, 14, 16, EW (up to Week 16)
Percentage of participants with >=50 percent improvement from Baseline in EASI
Timeframe: Weeks 1, 2, 4, 8, 12, 14, 16, EW (up to Week 16)
Percentage of participants with >=75 percent improvement from Baseline in EASI
Timeframe: Weeks 1, 2, 4, 8, 12, 14, 16, EW (up to Week 16)
Mean change from Baseline in total severity score (TSS)
Timeframe: Weeks 1, 2, 4, 8, 12, 14, 16, EW (up to Week 16)
Mean percent change from Baseline in TSS
Timeframe: Week 1, 2, 4, 8, 12, 14, 16, EW (up to Week 16)
Mean change from Baseline in individual signs of TSS
Timeframe: Weeks 1, 2, 4, 8, 12, 14, 16, EW (up to Week 16)
Mean percent change from Baseline in individual signs of TSS
Timeframe: Week 1, 2, 4, 8, 12, 14, 16, EW (up to Week 16)
Mean change from Baseline in body surface area (percent BSA)
Timeframe: Weeks 1, 2, 4, 8, 12, 14, 16, EW (up to Week 16)
Mean change from Baseline in IGA score
Timeframe: Weeks 1, 2, 4, 8, 12, 14, 16, EW (up to Week 16)
Percentage of participants who have an IGA score of clear or almost clear (0 or 1) and a minimum 2 grade improvement in IGA score from Baseline to each study visit
Timeframe: Weeks 1, 2, 4, 8, 12, 14, 16, EW (up to week 16)
Number of participants with treatment emergent adverse events (TEAEs) and serious TEAEs
Timeframe: Weeks 1, 2, 4, 8, 12, 14, EW (up to week 14)
Number of participants with reported tolerability score of 0 to 4 over time
Timeframe: Week 1, 2, 4, 8, 12, 14, EW (up to Week 14)
Change from Baseline in albumin and total protein
Timeframe: Week 1, 2, 4, 8, 12, 14, EW (up to week 14)
Change from Baseline in alkaline phosphatase (alk.phosph.), alanine aminotransferase (ALT), aspartate aminotransferase (AST) and gamma glutamyl transferase (GGT)
Timeframe: Week 2, 4, 8, 12, 14, EW (up to week 14)
Change from Baseline in direct and total bilirubin, creatinine and urate
Timeframe: Week 2, 4, 8, 12, 14, EW (up to week 14)
Change from Baseline in calcium, chloride, Carbon dioxide (CO2), glucose, potassium, sodium, blood urea nitrogen (BUN)
Timeframe: Week 2, 4, 8, 12, 14, EW (up to week 14)
Number of participants with chemistry data of potential clinical importance
Timeframe: Week 2, 4, 8, 12, 14, EW (up to week 14)
Change from Baseline in basophils, eosinophils, lymphocytes, monocytes, neutrophils, platelet, leukocytes count
Timeframe: Week 2, 4, 8, 12, 14, EW (up to week 14)
Change from Baseline in hematocrit levels
Timeframe: Week 2, 4, 8, 12, 14, EW (up to week 14)
Change from Baseline in hemoglobin and mean corpuscle hemoglobin concentration (MCHC)
Timeframe: Week 2, 4, 8, 12, 14, EW (up to week 14)
Change from Baseline in mean corpuscle hemoglobin (MCH)
Timeframe: Week 2, 4, 8, 12, 14, EW (up to week 14)
Change from Baseline in mean corpuscle volume (MCV)
Timeframe: Week 2, 4, 8, 12, 14, EW (up to week 14)
Change from Baseline in erythrocyte count
Timeframe: Weeks 2, 4, 8, 12, 14, EW (week up to 14)
Number of participants with hematology data of potential clinical importance
Timeframe: Baseline, Week 2, 4, 8, 12, 14, early withdrawal, and post screen (up to Week 16)
Change from Baseline in total T lymphocytes (lympho), B lympho, natural killer (NK) lymphocytes and treg (Foxp3) levels
Timeframe: Week, 4, 8 and 12
Number of participants with immunopheotyping data outside the reference range
Timeframe: Baseline, Week, 4, 8, 12 and post-screen (up to Week 16)
Change from Baseline in immunoglobin (Ig) A, IgG and IgM levels
Timeframe: Week, 4, 8 and 12
Number of participants with immunoglobulin data outside the reference range
Timeframe: Baseline, Week, 4, 8, 12, post-screen (up to Week 16)
Change from Baseline in systolic blood pressure (SBP) and diastolic blood pressure (DBP)
Timeframe: Week 1, 2, 4, 8, 12, 14, EW (up to week 14)
Change from Baseline in pulse rate
Timeframe: Week 1, 2, 4, 8, 12, 14, EW (up to week 14)
Change from Baseline in temperature
Timeframe: Week 1, 2, 4, 8, 12, 14, EW (up to week 14)
Number of participants with vital signs of potential clinical importance
Timeframe: Baseline, Week 2, 4, 8, 12, 14, EW (up to week 14)
Number of participants with abnormal electrocardiogram (ECG) findings
Timeframe: Baseline, Week 1, 12, 14, EW ( up to Week 14), post-screen
Interventions:
Drug: GSK2894512 1% Cream
Drug: GSK2894512 0.5% Cream
Drug: Vehicle cream
Enrollment:
247
Observational study model:
Not applicable
Primary completion date:
2017-12-01
Time perspective:
Not applicable
Clinical publications:
Johnny Peppers, Amy Paller, Tomoko Maeda-Chubachi, Sterling Wu, Kevin Robbins, Kelly Gallagher, John Kraus.A Phase 2, Dose-Finding Study of Tapinarof (GSK2894512) Cream for the Treatment of Atopic Dermatitis.J Am Acad Dermatol.2018;80(1):89-98.e3
DOI: 10.1016/j.jaad.2018.06.047
PMID: 30554600
Medical condition
Dermatitis, Atopic
Product
tapinarof
Collaborators
Not applicable
Study date(s)
December 2015 to January 2017
Type
Interventional
Phase
2
Participation criteria
Sex
Female & Male
Age
12 - 65 years
Accepts healthy volunteers
No
- Male or female between 12 and 65 years of age inclusive, at the time of signing the informed consent
- Diagnosis of atopic dermatitis according to Hanifin and Rajka criteria and having active inflammation.
- Unstable course of atopic dermatitis (spontaneously improving or rapidly deteriorating) as determined by the investigator over the previous 4 weeks prior to Baseline.
- Concurrent conditions and history of other diseases: 1) Immunocompromized (eg, lymphoma, acquired immunodeficiency syndrome, Wiskott-Aldrich Syndrome) or have a history of malignant disease within 5 years before the baseline visit; 2) Chronic or acute infection requiring treatment with systemic antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 4 weeks before the baseline visit; 3) Active acute bacterial, fungal, or viral (eg, herpes simplex, herpes zoster, chicken pox) skin infection within 1 week before the baseline visit; 4) Any other concomitant skin disorder (eg, generalized erythroderma such as Netherton’s Syndrome, or psoriasis); pigmentation, or extensive scarring that in the opinion of the investigator may interfere with the evaluation of AD lesions or compromise subject safety; 5) Presence of AD lesions only on the hands or feet without prior history of involvement of other classical areas of involvement such as the face or the folds; 6) Other types of eczema.
Inclusion and exclusion criteria
Inclusion criteria:
- Male or female between 12 and 65 years of age inclusive, at the time of signing the informed consent
- Diagnosis of atopic dermatitis according to Hanifin and Rajka criteria and having active inflammation.
- Body surface area involvement >=5% and <=35%, excluding scalp, at Screening and Baseline.
- An IGA of atopic dermatitis score of >=3 at Baseline.
- At least one target lesion that measure at least 3 centimetre (cm) х 3 cm in size at Screening and Baseline and must be representative of the subject’s disease state, but not located on the hands, feet, or genitalia.
- A female subject is eligible to participate if she is not pregnant (as confirmed by a negative urine human chorionic gonadotrophin test), not lactating, and at least one of the following conditions applies: Non-reproductive potential defined as: 1) Pre-menopausal females with one of the following procedures documented: tubal ligation; hysteroscopic tubal occlusion procedure with follow-up confirmation of bilateral tubal occlusion; hysterectomy; bilateral oophorectomy. 2) Post-menopausal defined as 12 months of spontaneous amenorrhea (in questionable cases a blood sample with simultaneous follicle stimulating hormone and estradiol levels consistent with menopause and falling into the central laboratory’s postmenopausal reference range is confirmatory). Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt are required to use one of the highly effective contraception methods if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrolment; Reproductive potential and agrees to follow one of the options listed in the modified list of highly effective methods for avoiding pregnancy in females of reproductive potential from 30 days prior to the first dose of study medication and until after the last dose of study medication and completion of the follow-up visit.
Exclusion criteria:
- Unstable course of atopic dermatitis (spontaneously improving or rapidly deteriorating) as determined by the investigator over the previous 4 weeks prior to Baseline.
- Concurrent conditions and history of other diseases: 1) Immunocompromized (eg, lymphoma, acquired immunodeficiency syndrome, Wiskott-Aldrich Syndrome) or have a history of malignant disease within 5 years before the baseline visit; 2) Chronic or acute infection requiring treatment with systemic antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 4 weeks before the baseline visit; 3) Active acute bacterial, fungal, or viral (eg, herpes simplex, herpes zoster, chicken pox) skin infection within 1 week before the baseline visit; 4) Any other concomitant skin disorder (eg, generalized erythroderma such as Netherton’s Syndrome, or psoriasis); pigmentation, or extensive scarring that in the opinion of the investigator may interfere with the evaluation of AD lesions or compromise subject safety; 5) Presence of AD lesions only on the hands or feet without prior history of involvement of other classical areas of involvement such as the face or the folds; 6) Other types of eczema.
- A history or ongoing serious illness or medical, physical, or psychiatric condition(s) that, in the investigator’s opinion, may interfere with the subject’s completion of the study.
- Known hypersensitivity to study treatment excipients.
- Current or chronic history of liver disease, known hepatic or biliary abnormalities (with the exception of Gilbert’s syndrome or asymptomatic gallstones), presence of hepatitis B surface antigen (HBsAg), or positive hepatitis C antibody test result within 3 months of screening.
- Liver function tests: alanine aminotransferase (ALT) >=2x upper limit of normal (ULN); alkaline phosphatase and bilirubin >1.5xULN (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%).
- QTc >=450 milliseconds (msec) or QTc >=480 msec for subjects with bundle branch block. NOTES: The QTc is the QT interval corrected for heart rate according to Fridericia’s formula (QTcF), with machine over-read. The QTc should be based on a single ECG obtained over a brief recording period. If QTc is outside of the threshold value, triplicate ECGs may be performed with the QTc values averaged.
- Ultraviolet (UV) light therapy or prolonged exposure to natural or artificial sources of UV radiation (eg, sunlight or tanning booth) within 4 weeks prior to the baseline visit and/or intention to have such exposure during the study, which is thought by the investigator to potentially impact the subject’s atopic dermatitis.
- Used any of the following treatments within the indicated washout period before the baseline visit: 12 weeks or 5 half-lives (whichever is longer) – biologic agents (eg, 18 weeks for omalizumab); 8 weeks – cyclosporin, methotrexate, azathioprine, or other systemic immunosuppressive or immunomodulating agents (eg, mycophenolate or tacrolimus); 4 weeks – systemic corticosteroids or adrenocorticotropic hormone analogs; 2 weeks – topical treatments: corticosteroids, calcineurin inhibitors, or coal tar (on the body); 2 weeks – immunizations; sedating antihistamines (non sedating antihistamines are permitted); 1 week – topical antibiotics, antibacterial cleansing body wash/soap or diluted sodium hypochlorite “bleach” baths.
- Participated in a clinical study and received an investigational product within the following time period prior to the baseline visit: 4 weeks, 5 half-lives, or twice the duration of the biological effect of the investigational product (whichever is longer).
- History of alcohol or other substance abuse within the last 2 years.
- Participated in a previous study using GSK2894512 (or WBI-1001).
Trial location(s)
Location
GSK Investigational Site
Andover, Massachusetts, United States, 01810
Status
Study Complete
Location
GSK Investigational Site
Atlanta, Georgia, United States, 30342
Status
Study Complete
Location
GSK Investigational Site
Chicago, Illinois, United States, 60611
Status
Study Complete
Location
GSK Investigational Site
Cincinnati, Ohio, United States, 45255
Status
Study Complete
Location
GSK Investigational Site
Cranston, Rhode Island, United States, 2910
Status
Study Complete
Location
GSK Investigational Site
Denver, Colorado, United States, 80220
Status
Study Complete
Location
GSK Investigational Site
Fort Smith, Arkansas, United States, 72916
Status
Study Complete
Location
GSK Investigational Site
Fresno, California, United States, 93720-2933
Status
Study Complete
Location
GSK Investigational Site
Fridley, Minnesota, United States, 55432
Status
Study Complete
Location
GSK Investigational Site
Greer, South Carolina, United States, 29650
Status
Study Complete
Location
GSK Investigational Site
Indianapolis, Indiana, United States, 46256
Status
Study Complete
Location
GSK Investigational Site
Irvine, California, United States, 92697
Status
Study Complete
Location
GSK Investigational Site
Los Angeles, California, United States, 90045
Status
Study Complete
Location
GSK Investigational Site
New Albany, Indiana, United States, 47150
Status
Study Complete
Location
GSK Investigational Site
New Orleans, Louisiana, United States, 70115
Status
Study Complete
Location
GSK Investigational Site
New York, New York, United States, 10022
Status
Study Complete
Location
GSK Investigational Site
Norfolk, Virginia, United States, 23507
Status
Study Complete
Location
GSK Investigational Site
North Logan, Connecticut, United States, 06032
Status
Study Complete
Location
GSK Investigational Site
Oceanside, California, United States, 92056
Status
Study Complete
Location
GSK Investigational Site
Overland Park, Kansas, United States, 66215
Status
Study Complete
Location
GSK Investigational Site
Philadelphia, Pennsylvania, United States, 19103
Status
Study Complete
Location
GSK Investigational Site
Pittsburgh, Pennsylvania, United States, 15213
Status
Study Complete
Location
GSK Investigational Site
Richmond Hill, Ontario, Canada, L4B 1A5
Status
Study Complete
Location
GSK Investigational Site
San Antonio, Texas, United States, 78218
Status
Study Complete
Location
GSK Investigational Site
San Antonio, Texas, United States, 78229
Status
Study Complete
Location
GSK Investigational Site
Santa Ana, California, United States, 92701
Status
Study Complete
Location
GSK Investigational Site
Seattle, Washington, United States, 98101
Status
Study Complete
Location
GSK Investigational Site
St. Joseph, Missouri, United States, 64506
Status
Study Complete
Location
GSK Investigational Site
Surrey, British Columbia, Canada, V3R 6A7
Status
Study Complete
Location
GSK Investigational Site
West Bloomfield, Michigan, United States, 48322
Status
Study Complete
Study documents
Clinical study report
Available language(s): English
Protocol
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Results posted on ClinicalTrials.gov
Recruitment status
Completed
Actual primary completion date
2017-12-01
Actual study completion date
2017-12-01
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Additional information
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website